ImmunityBio, Inc.

IBRX

NASDAQ

Healthcare

Biotechnology

San Diego, CA, US671 employeesimmunitybio.com

$7.30

+0.17(2.31%)

Mkt Cap $7.5B

$1.89

$11.55

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Product (98.8%), Product And Service Other (1.2%).

8-K

ImmunityBio, Inc. entered into a Second Amendment to its Revenue Interest Purchase Agreement on March 30, 2026, securing an additional $75 million in non-dilutive financing and increasing the total committed capital to $375 million.

$7.5B

Market Cap

$118M

Revenue

-$365M

Net Income

Employees671

Fundamentals

How The Business Makes Money

Revenue by Segment

Product98.8%($127M)

Product And Service Other1.2%($2M)

Revenue by Geography

US98.9%($127M)

Europe1.1%($1M)

Activity

What Changed Recently

Financial Results

Feb 22, 2026

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am

Material Agreement

Jan 25, 2026

Entry into a Material Definitive Agreement. On January 23, 2026, ImmunityBio, Inc. (the “Company”) entered into a letter amendment (the “Convertible Note Amendm

Financial Results

Jan 14, 2026

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am

Material Agreement+4 More

Mar 30, 2026

above is incorporated by reference into this Item 2.03. | Item 7.01 | Regulation FD Disclosure. | |---|---| On March 31, 2026, the Company issued a press releas

Other Event

Feb 17, 2026

, including Exhibit 99.1 attached hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise

Peer Companies

Company	Price	Change	Market Cap	P/E
COGTCogent Biosciences, Inc.	$35.31	+0.21%	$5.7B	-7.3
LQDALiquidia Corporation	$37.63	+0.43%	$3.3B	-44.9
DNLIDenali Therapeutics Inc.	$20.61	+4.73%	$3.3B	-7.2
BEAMBeam Therapeutics Inc.	$24.65	+1.78%	$2.5B	-32.4
RCUSArcus Biosciences, Inc.	$22.95	+5.06%	$2.3B	-6.5
ETNBETNB	$14.84	+0.00%	$2.2B	—
AGIOAgios Pharmaceuticals, In...	$35.17	+2.87%	$2.1B	-4.0
GLPGGalapagos N.V.	$29.40	-1.22%	$1.9B	5.6

Analyst View

Company Profile

CIK0001326110

ISINUS45256X1037

CUSIP45256X103

Phone858 633 0300

Address3530 John Hopkins Court, San Diego, CA, 92121, US

SEC EDGAR